{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:28:47Z","timestamp":1792884527549,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jad.2023.08.027","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T01:46:51Z","timestamp":1691372811000},"page":"893-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder"],"prefix":"10.1016","volume":"340","author":[{"given":"Shakila","family":"Meshkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ceban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"285","key":"10.1016\/j.jad.2023.08.027_bb0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2021.02.027","article-title":"Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder","volume":"15","author":"Arnaud","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.08.027_bb0010","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2023.08.027_bb0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuropharm.2015.11.019","article-title":"During postnatal development endogenous neurosteroids influence GABA-ergic neurotransmission of mouse cortical neurons","volume":"103","author":"Brown","year":"2016","journal-title":"Neuropharmacology"},{"issue":"421","key":"10.1016\/j.jad.2023.08.027_bb0020","article-title":"Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: a phase 2, open-label study","volume":"15","author":"Bullock","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jad.2023.08.027_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2806","article-title":"A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults","volume":"37","author":"Bullock","year":"2022","journal-title":"Hum. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2023.08.027_bb0030","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of Zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.08.027_bb0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euroneuro.2020.09.636","article-title":"Add-on benzodiazepine treatment in patients with major depressive disorder\u2013results from a European cross-sectional multicenter study","volume":"41","author":"Dold","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.08.027_bb0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jad.2021.09.063","article-title":"Pregabalin augmentation of antidepressants in major depression-results from a European multicenter study","volume":"296","author":"Dold","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.jad.2023.08.027_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.08.027_bb1000","series-title":"Poster presented at: psych Congress 2020 Virtual Experience","article-title":"Open-label, Phase 2 trial of the oral neuroactive steroid GABAA receptor positive allosteric modulator zuranolone in bipolar disorder I and II","author":"Gunduz-Bruce","year":"2020"},{"key":"10.1016\/j.jad.2023.08.027_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eplepsyres.2017.05.001","article-title":"Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models","volume":"134","author":"Hammond","year":"2017","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.jad.2023.08.027_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2023.08.027_bb0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jad.2023.08.027_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/hup.189","article-title":"Antidepressants in clinical practice: limitations of assessment methods and drug response","volume":"16","author":"Kennedy","year":"2001","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jad.2023.08.027_bb0070","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.3390\/ijms21249391","article-title":"Neurosteroids and focal epileptic disorders","volume":"21","author":"Levesque","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jad.2023.08.027_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1515\/bmc-2012-0033","article-title":"Neurosteroids and GABAergic signaling in health and disease","volume":"4","author":"MacKenzie","year":"2013","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.jad.2023.08.027_bb0080","first-page":"3065","article-title":"Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)","author":"Maninger","year":"2009","journal-title":"Front. Neuroendocrinol."},{"issue":"18","key":"10.1016\/j.jad.2023.08.027_bb0085","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids: 2:3\u03b1-hydroxy-3\u03b2methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-aminobutyric acid)a receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jad.2023.08.027_bb0090","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/da.22063","article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions","volume":"30","author":"McIntyre","year":"2013","journal-title":"Depress. Anxiety"},{"issue":"156","key":"10.1016\/j.jad.2023.08.027_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"1","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2023.08.027_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jad.2023.08.027_bb0105","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post- partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.08.027_bb0110","article-title":"Antidepressants plus benzodiazepines for adults with major depression","volume":"6","author":"Ogawa","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2023.08.027_bb0115","doi-asserted-by":"crossref","first-page":"12351","DOI":"10.1111\/jne.12351","article-title":"Neurosteroidogenesis today: novel targets for neuroactive steroid synthesis and action and their relevance for translational research","volume":"28","author":"Porcu","year":"2016","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.jad.2023.08.027_bb0120","first-page":"113","article-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials","volume":"18","author":"Reddy","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.jad.2023.08.027_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.25008","article-title":"Brexanolone as adjunctive therapy in super-refractory status epilepticus","volume":"82","author":"Rosenthal","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jad.2023.08.027_bb0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jad.2023.08.027_bb0135","series-title":"Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE217 in Major Depressive Disorder [Internet]","year":"2021"},{"key":"10.1016\/j.jad.2023.08.027_bb0140","series-title":"Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD [Internet]","author":"Sage Therapeutics Announces Positive Interim","year":"2021"},{"issue":"7","key":"10.1016\/j.jad.2023.08.027_bb0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABAA receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.jad.2023.08.027_bb0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropharm.2011.07.026","article-title":"Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes","volume":"62","author":"Smith","year":"2012","journal-title":"Neuropharmacology"},{"issue":"308","key":"10.1016\/j.jad.2023.08.027_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jad.2022.03.068","article-title":"Patient-reported healthrelated quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder","volume":"1","author":"Suthoff","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.08.027_bb0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discov. Today"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723010030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723010030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:29:45Z","timestamp":1759033785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723010030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"alternative-id":["S0165032723010030"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.08.027","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}